Access the full text.
Sign up today, get DeepDyve free for 14 days.
( Harris PA , TaylorR, ThielkeR, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform2009; 42:377–81.18929686)
Harris PA , TaylorR, ThielkeR, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform2009; 42:377–81.18929686Harris PA , TaylorR, ThielkeR, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform2009; 42:377–81.18929686, Harris PA , TaylorR, ThielkeR, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform2009; 42:377–81.18929686
A. Cusini, C. Béguelin, S. Stampf, K. Boggian, C. Garzoni, M. Koller, O. Manuel, P. Meylan, N. Mueller, H. Hirsch, M. Weisser, C. Berger, C. Delden, R. Achermann, P. Amico, J. Aubert, V. Banz, G. Beldi, C. Benden, I. Binet, P. Bochud, H. Bucher, L. Bühler, Thierry Carell, Emmanuelle Catana, Y. Chalandon, S. Geest, O. Rougemont, M. Dickenmann, M. Duchosal, L. Elkrief, T. Fehr, S. Ferrari-Lacraz, Paola Soccal, Christophe Gaudet, E. Giostra, D. Golshayan, K. Hadaya, Jörg Halter, D. Heim, C. Hess, S. Hillinger, G. Hofbauer, U. Huynh-Do, F. Immer, R. Klaghofer, Bettina Laesser, R. Lehmann, C. Lovis, H. Marti, Pierre-Yves Martin, P. Mohacsi, P. Morel, Ulrike Mueller, Helen Mueller‐McKenna, Antonia Müller, T. Müller, B. Müllhaupt, D. Nadal, M. Pascual, Jakob Passweg, J. Rick, E. Roosnek, A. Rosselet, Silvia Rothlin, F. Ruschitzka, U. Schanz, S. Schaub, A. Schnyder, C. Seiler, J. Steiger, G. Stirnimann, C. Toso, J. Venetz, J. Villard, Madeleine Wick, Markus Wilhelm, P. Yerly (2018)
Clostridium difficile infection is associated with graft loss in solid organ transplant recipientsAmerican Journal of Transplantation, 18
F. Lessa, Yi Mu, Wendy Bamberg, Z. Beldavs, G. Dumyati, J. Dunn, M. Farley, S. Holzbauer, J. Meek, Erin Phipps, L. Wilson, L. Winston, Jessica Cohen, B. Limbago, S. Fridkin, D. Gerding, L. McDonald (2015)
Burden of Clostridium difficile infection in the United States.The New England journal of medicine, 372 9
( Schluger A , RosenblattR, KnottsR, et al. Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients. Transpl Infect Dis2019; 21:e13184.31571380)
Schluger A , RosenblattR, KnottsR, et al. Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients. Transpl Infect Dis2019; 21:e13184.31571380Schluger A , RosenblattR, KnottsR, et al. Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients. Transpl Infect Dis2019; 21:e13184.31571380, Schluger A , RosenblattR, KnottsR, et al. Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients. Transpl Infect Dis2019; 21:e13184.31571380
B. Rogala, G. Malat, D. Lee, M. Harhay, A. Doyle, T. Bias (2016)
Identification of Risk Factors Associated With Clostridium difficile Infection in Liver Transplantation Recipients: A Single-Center Analysis.Transplantation proceedings, 48 8
D. Gerding, C. Kelly, G. Rahav, Christine Lee, E. Dubberke, Princy Kumar, B. Yacyshyn, D. Kao, K. Eves, M. Ellison, M. Hanson, D. Guris, M. Dorr (2018)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for RecurrenceClinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 67
( Wilcox MH , GerdingDN, PoxtonIR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med2017; 376:305–17.28121498)
Wilcox MH , GerdingDN, PoxtonIR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med2017; 376:305–17.28121498Wilcox MH , GerdingDN, PoxtonIR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med2017; 376:305–17.28121498, Wilcox MH , GerdingDN, PoxtonIR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med2017; 376:305–17.28121498
(2018)
Swiss Transplant Cohort Study. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients
M. Sims (2017)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection., 376
( Rogala BG , MalatGE, LeeDH, et al. Identification of risk factors associated with Clostridium difficile infection in liver transplantation recipients: a single-center analysis. Transplant Proc2016; 48:2763–8.27788814)
Rogala BG , MalatGE, LeeDH, et al. Identification of risk factors associated with Clostridium difficile infection in liver transplantation recipients: a single-center analysis. Transplant Proc2016; 48:2763–8.27788814Rogala BG , MalatGE, LeeDH, et al. Identification of risk factors associated with Clostridium difficile infection in liver transplantation recipients: a single-center analysis. Transplant Proc2016; 48:2763–8.27788814, Rogala BG , MalatGE, LeeDH, et al. Identification of risk factors associated with Clostridium difficile infection in liver transplantation recipients: a single-center analysis. Transplant Proc2016; 48:2763–8.27788814
K. Mullane, E. Dubberke (2019)
Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of PracticeClinical Transplantation, 33
( Parmar SR , BhattV, YangJ, et al. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract2014; 20:172–82.23804627)
Parmar SR , BhattV, YangJ, et al. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract2014; 20:172–82.23804627Parmar SR , BhattV, YangJ, et al. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract2014; 20:172–82.23804627, Parmar SR , BhattV, YangJ, et al. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract2014; 20:172–82.23804627
( Charlson ME , PompeiP, AlesKL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis1987; 40:373–83.3558716)
Charlson ME , PompeiP, AlesKL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis1987; 40:373–83.3558716Charlson ME , PompeiP, AlesKL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis1987; 40:373–83.3558716, Charlson ME , PompeiP, AlesKL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis1987; 40:373–83.3558716
( McDonald LC , GerdingDN, JohnsonS, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis2018; 66:e1–48.29462280)
McDonald LC , GerdingDN, JohnsonS, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis2018; 66:e1–48.29462280McDonald LC , GerdingDN, JohnsonS, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis2018; 66:e1–48.29462280, McDonald LC , GerdingDN, JohnsonS, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis2018; 66:e1–48.29462280
( Ilett EE , HellebergM, ReekieJ, et al. Incidence rates and risk factors of Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients. Open Forum Infect Dis2019; 6:ofz086.30949533)
Ilett EE , HellebergM, ReekieJ, et al. Incidence rates and risk factors of Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients. Open Forum Infect Dis2019; 6:ofz086.30949533Ilett EE , HellebergM, ReekieJ, et al. Incidence rates and risk factors of Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients. Open Forum Infect Dis2019; 6:ofz086.30949533, Ilett EE , HellebergM, ReekieJ, et al. Incidence rates and risk factors of Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients. Open Forum Infect Dis2019; 6:ofz086.30949533
Aaron Schluger, R. Rosenblatt, Rita Knotts, E. Verna, Marcus Pereira (2019)
Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipientsTransplant Infectious Disease, 21
S. Bunnapradist, L. Neri, W. Wong, K. Lentine, T. Burroughs, B. Pinsky, S. Takemoto, M. Schnitzler (2008)
Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality.American journal of kidney diseases : the official journal of the National Kidney Foundation, 51 3
M. Charlson, P. Pompei, Kathy Ales, C. MacKenzie (1987)
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.Journal of chronic diseases, 40 5
( Zar FA , BakkanagariSR, MoorthiKM, DavisMB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease severity. Clin Infect Dis2007; 45: 302–7.17599306)
Zar FA , BakkanagariSR, MoorthiKM, DavisMB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease severity. Clin Infect Dis2007; 45: 302–7.17599306Zar FA , BakkanagariSR, MoorthiKM, DavisMB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease severity. Clin Infect Dis2007; 45: 302–7.17599306, Zar FA , BakkanagariSR, MoorthiKM, DavisMB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease severity. Clin Infect Dis2007; 45: 302–7.17599306
( Dubberke ER , GerdingDN, KellyCP, et al. Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection. Open Forum Infect Dis2020; 7:ofaa157.32523972)
Dubberke ER , GerdingDN, KellyCP, et al. Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection. Open Forum Infect Dis2020; 7:ofaa157.32523972Dubberke ER , GerdingDN, KellyCP, et al. Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection. Open Forum Infect Dis2020; 7:ofaa157.32523972, Dubberke ER , GerdingDN, KellyCP, et al. Efficacy of bezlotoxumab in participants receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridioides (Clostridium) difficile infection. Open Forum Infect Dis2020; 7:ofaa157.32523972
(1989)
Fecal microbiota for transplantation : safety alert — risk of serious adverse events likely due to transmission of pathogenic organisms . 2020
Laura Prohaska, Zahra Mahmoudjafari, L. Shune, Anurag Singh, T. Lin, S. Abhyankar, S. Ganguly, Dennis Grauer, J. McGuirk, L. Clough (2018)
Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.Hematology/oncology and stem cell therapy, 11 4
C. Kelly, J. Lamont (2008)
Clostridium difficile--more difficult than ever.The New England journal of medicine, 359 18
S. Parmar, V. Bhatt, Jie Yang, Qiao Zhang, M. Schuster (2014)
A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignanciesJournal of Oncology Pharmacy Practice, 20
(2021)
and Drug Administration
( Kelly CP , LaMontJT. Clostridium difficile—more difficult than ever. N Engl J Med2008; 359:1932–40.18971494)
Kelly CP , LaMontJT. Clostridium difficile—more difficult than ever. N Engl J Med2008; 359:1932–40.18971494Kelly CP , LaMontJT. Clostridium difficile—more difficult than ever. N Engl J Med2008; 359:1932–40.18971494, Kelly CP , LaMontJT. Clostridium difficile—more difficult than ever. N Engl J Med2008; 359:1932–40.18971494
( Fekety R , SilvaJ, KauffmanC, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med1989; 86:15–9.)
Fekety R , SilvaJ, KauffmanC, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med1989; 86:15–9.Fekety R , SilvaJ, KauffmanC, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med1989; 86:15–9., Fekety R , SilvaJ, KauffmanC, et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med1989; 86:15–9.
( Bunnapradist S , NeriL, WongW, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis2008; 51:478–86.18295064)
Bunnapradist S , NeriL, WongW, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis2008; 51:478–86.18295064Bunnapradist S , NeriL, WongW, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis2008; 51:478–86.18295064, Bunnapradist S , NeriL, WongW, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis2008; 51:478–86.18295064
( Gerding DN , KellyCP, RahavG, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis2018; 67:649–56.29538686)
Gerding DN , KellyCP, RahavG, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis2018; 67:649–56.29538686Gerding DN , KellyCP, RahavG, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis2018; 67:649–56.29538686, Gerding DN , KellyCP, RahavG, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence. Clin Infect Dis2018; 67:649–56.29538686
( Cusini A , BéguelinC, StampfS, et al; Swiss Transplant Cohort Study. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients. Am J Transplant2018; 18:1745–54.29349869)
Cusini A , BéguelinC, StampfS, et al; Swiss Transplant Cohort Study. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients. Am J Transplant2018; 18:1745–54.29349869Cusini A , BéguelinC, StampfS, et al; Swiss Transplant Cohort Study. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients. Am J Transplant2018; 18:1745–54.29349869, Cusini A , BéguelinC, StampfS, et al; Swiss Transplant Cohort Study. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients. Am J Transplant2018; 18:1745–54.29349869
( Mullane KM , DubberkeER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: guidelines from the American Society of Transplantation community of practice. Clin Transplant2019; 33:e13564.31002420)
Mullane KM , DubberkeER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: guidelines from the American Society of Transplantation community of practice. Clin Transplant2019; 33:e13564.31002420Mullane KM , DubberkeER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: guidelines from the American Society of Transplantation community of practice. Clin Transplant2019; 33:e13564.31002420, Mullane KM , DubberkeER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: guidelines from the American Society of Transplantation community of practice. Clin Transplant2019; 33:e13564.31002420
F. Zar, Srinivasa Bakkanagari, K. Moorthi, Melinda Davis (2007)
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 45 3
(2017)
MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection
R. Dallal, B. Harbrecht, Arthur Boujoukas, C. Sirio, L. Farkas, Kenneth Lee, R. Simmons (2002)
Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and ComplicationsAnnals of Surgery, 235
( Zinplava (bezlotoxumab) [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2016.)
Zinplava (bezlotoxumab) [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2016.Zinplava (bezlotoxumab) [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2016., Zinplava (bezlotoxumab) [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2016.
( Prohaska L , MahmoudjafariZ, ShuneL, et al. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther2018; 11:233–40.29928848)
Prohaska L , MahmoudjafariZ, ShuneL, et al. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther2018; 11:233–40.29928848Prohaska L , MahmoudjafariZ, ShuneL, et al. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther2018; 11:233–40.29928848, Prohaska L , MahmoudjafariZ, ShuneL, et al. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther2018; 11:233–40.29928848
E. Ilett, M. Helleberg, J. Reekie, Daniel Murray, S. Wulff, Mark Khurana, A. Mocroft, G. Daugaard, M. Perch, A. Rasmussen, S. Sørensen, F. Gustafsson, N. Frimodt-Møller, H. Sengeløv, J. Lundgren (2019)
Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant RecipientsOpen Forum Infectious Diseases, 6
Fecal microbiota for transplantation: safety alert-risk of serious adverse events likely due to transmission of pathogenic organisms
P. Harris, Robert Taylor, R. Thielke, Jonathon Payne, N. Gonzalez, J. Conde (2009)
Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of biomedical informatics, 42 2
J. Oksi, A. Aalto, P. Saila, Terhi Partanen, V. Anttila, E. Mattila (2019)
Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in FinlandEuropean Journal of Clinical Microbiology & Infectious Diseases, 38
E. Dubberke, D. Gerding, C. Kelly, K. Garey, G. Rahav, Audrey Mosley, R. Tipping, M. Dorr (2020)
Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile InfectionOpen Forum Infectious Diseases, 7
( Hengel RL , RitterTE, NathanRV, et al. Real-world experience of bezlotoxumab for prevention of Clostridioides difficile infection: a retrospective multicenter cohort study. Open Forum Infect Dis2020; 7:ofaa097.32363211)
Hengel RL , RitterTE, NathanRV, et al. Real-world experience of bezlotoxumab for prevention of Clostridioides difficile infection: a retrospective multicenter cohort study. Open Forum Infect Dis2020; 7:ofaa097.32363211Hengel RL , RitterTE, NathanRV, et al. Real-world experience of bezlotoxumab for prevention of Clostridioides difficile infection: a retrospective multicenter cohort study. Open Forum Infect Dis2020; 7:ofaa097.32363211, Hengel RL , RitterTE, NathanRV, et al. Real-world experience of bezlotoxumab for prevention of Clostridioides difficile infection: a retrospective multicenter cohort study. Open Forum Infect Dis2020; 7:ofaa097.32363211
( Oksi J , AaltoA, SäiläP, et al. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland. Eur J Clin Microbiol Infect Dis2019; 38:1947–52.31359254)
Oksi J , AaltoA, SäiläP, et al. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland. Eur J Clin Microbiol Infect Dis2019; 38:1947–52.31359254Oksi J , AaltoA, SäiläP, et al. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland. Eur J Clin Microbiol Infect Dis2019; 38:1947–52.31359254, Oksi J , AaltoA, SäiläP, et al. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland. Eur J Clin Microbiol Infect Dis2019; 38:1947–52.31359254
( Dallal RM , HarbrechtBG, BoujoukasAJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg2002; 235:363–72.11882758)
Dallal RM , HarbrechtBG, BoujoukasAJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg2002; 235:363–72.11882758Dallal RM , HarbrechtBG, BoujoukasAJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg2002; 235:363–72.11882758, Dallal RM , HarbrechtBG, BoujoukasAJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg2002; 235:363–72.11882758
( US Food and Drug Administration. Fecal microbiota for transplantation: safety alert—risk of serious adverse events likely due to transmission of pathogenic organisms. 2020. https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission. Accessed 23 March 2021.)
US Food and Drug Administration. Fecal microbiota for transplantation: safety alert—risk of serious adverse events likely due to transmission of pathogenic organisms. 2020. https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission. Accessed 23 March 2021.US Food and Drug Administration. Fecal microbiota for transplantation: safety alert—risk of serious adverse events likely due to transmission of pathogenic organisms. 2020. https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission. Accessed 23 March 2021., US Food and Drug Administration. Fecal microbiota for transplantation: safety alert—risk of serious adverse events likely due to transmission of pathogenic organisms. 2020. https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission. Accessed 23 March 2021.
( Paudel S , ZacharioudakisIM, ZervouFN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One2015; 10:e0124483.25886133)
Paudel S , ZacharioudakisIM, ZervouFN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One2015; 10:e0124483.25886133Paudel S , ZacharioudakisIM, ZervouFN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One2015; 10:e0124483.25886133, Paudel S , ZacharioudakisIM, ZervouFN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One2015; 10:e0124483.25886133
Robertfekety, Carolkauffman, B. Buggy, H. Deery, M. Arbor, R. Fekety (1989)
Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.The American journal of medicine, 86 1
( Lessa FC , MuY, BambergWM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med2015; 372:825–34.25714160)
Lessa FC , MuY, BambergWM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med2015; 372:825–34.25714160Lessa FC , MuY, BambergWM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med2015; 372:825–34.25714160, Lessa FC , MuY, BambergWM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med2015; 372:825–34.25714160
L. McDonald, D. Gerding, Stuart Johnson, J. Bakken, K. Carroll, S. Coffin, E. Dubberke, K. Garey, C. Gould, C. Kelly, V. Loo, Julia Sammons, Thomas Sandora, M. Wilcox (2018)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 66 7
R. Hengel, T. Ritter, Ramesh Nathan, L. Anglen, Claudia Schroeder, R. Dillon, S. Marcella, K. Garey (2020)
Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort StudyOpen Forum Infectious Diseases, 7
M. Wilcox, D. Gerding, I. Poxton, C. Kelly, Richard Nathan, T. Birch, O. Cornely, G. Rahav, E. Bouza, Christine Lee, G. Jenkin, Werner Jensen, You-Sun Kim, J. Yoshida, Lori Gabryelski, Alison Pedley, K. Eves, R. Tipping, D. Guris, N. Kartsonis, M. Dorr (2017)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile InfectionThe New England Journal of Medicine, 376
S. Paudel, I. Zacharioudakis, F. Zervou, P. Ziakas, E. Mylonakis (2015)
Prevalence of Clostridium difficile Infection among Solid Organ Transplant Recipients: A Meta-Analysis of Published StudiesPLoS ONE, 10
BackgroundBezlotoxumab significantly reduces the incidence of recurrent Clostridioides difficile infection (CDI); however, limited data are available in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients.MethodsWe conducted a single-center retrospective analysis comparing recurrent CDI in SOT and HCT recipients receiving standard of care alone (oral vancomycin, fidaxomicin, or metronidazole) or bezlotoxumab plus standard of care. The primary outcome was 90-day incidence of recurrent CDI, and secondary outcomes included 90-day hospital readmission, mortality, and incidence of heart failure exacerbation.ResultsOverall, 94 patients received bezlotoxumab plus standard of care (n = 38) or standard of care alone (n = 56). The mean age was 53 years; patients had a median of 3 prior Clostridioides difficile episodes and 4 risk factors for recurrent infection. Most patients were SOT recipients (76%), with median time to index CDI occurring 2.7 years after transplantation. Ninety-day recurrent CDI occurred in 16% (6/38) in the bezlotoxumab cohort compared to 29% (16/56) in the standard of care cohort (P = .13). Multivariable regression revealed that bezlotoxumab was associated with significantly lower odds of 90-day recurrent CDI (odds ratio, 0.28 [95% confidence interval, .08–.91]). There were no differences in secondary outcomes, and no heart failure exacerbations were observed.ConclusionsIn a cohort of primarily SOT recipients, bezlotoxumab was well tolerated and associated with lower odds of recurrent CDI at 90 days. Larger, prospective trials are needed to confirm these findings among SOT and HCT populations.
Open Forum Infectious Diseases – Oxford University Press
Published: Jun 4, 2021
Keywords: bezlotoxumab; CDI; Clostridioides difficile infection; transplant recipient
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.